Filter by: patients
Home > Community Treatment Reports and Side Effects > Dalfampridine (4-AP extended release) Treatment Report
What is Dalfampridine (4-AP extended release)?

Dalfampridine, is an extended release formulation of 4-aminopyridine or 4-AP. It is a potassium channel blocker that is indicated as a treatment to improve walking in patients with multiple sclerosis (MS). Dalfampridine was previously called Fampridine-SR during clinical trials.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
MS (Multiple Sclerosis) 510 101 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell
Improve mobility 220 112 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell
Walking problems 128 60 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell
Improve flexibility/strength 33 11 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_cant_tell
Fatigue 29 10 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell
Imbalance when walking 25 15 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell

See all 677 patients currently taking Dalfampridine (4-AP extended release)

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 20
Moderate
 30
Mild
 69
None
 149

Commonly reported side effects, conditions, and hospitalizations associated with Dalfampridine (4-AP extended release)

Insomnia 16
Dizziness 15
Nausea 8
Headaches 7
Constipation 7
Dizziness and feeling faint 6
See all 74 reported side effects ▼ See top 6 reported side effects ▲

Reported Dosages

Frequently reported dosages based on patients currently taking Dalfampridine (4-AP extended release). See all 43 dosages ►

  1 mg daily 2 daily 2 other daily 2 mg daily 5 mg daily 10 mg daily 15 mg daily 20 mg daily 30 mg daily 40 mg daily
  6 Number of Patients: 6 6 Number of Patients: 6 14 Number of Patients: 14 22 Number of Patients: 22 9 Number of Patients: 9 154 Number of Patients: 154 14 Number of Patients: 14 376 Number of Patients: 376 23 Number of Patients: 23 15 Number of Patients: 15  

Reported Stop Reasons

Why Patients Stopped Taking Dalfampridine (4-AP extended release) (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work 92   Did not seem to work: 46%
Side effects too severe 58   Side effects too severe: 29%
Other 38   Other: 19%
Doctor's advice 24   Doctor's advice: 12%
Expense 23   Expense: 12%
Personal research 7   Personal research: 4%
Course of treatment ended 5   Course of treatment ended: 3%
Change in health plan coverage 5   Change in health plan coverage: 3%
Not indicated 5   Not indicated: 3%

See all 192 patients who’ve stopped taking Dalfampridine (4-AP extended release)

Reported Duration See details about how long patients take this treatment ▼

Currently Taking Dalfampridine (4-AP extended release)

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more

Stopped Taking Dalfampridine (4-AP extended release)

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Dalfampridine (4-AP extended release)

Always
 211 79%
Usually
 41 15%
Sometimes
 4 1%
Never
 12 4%

Burden

Difficulty being on treatment

Burden of Dalfampridine (4-AP extended release)

Very
 4 1%
Somewhat
 14 5%
A little
 38 14%
Not at all
 212 79%

Cost

Paid out of pocket

Cost of Dalfampridine (4-AP extended release)

$200+
 6 3%
$100-199
 12 5%
$50-99
 49 21%
$25-49
 90 39%
< $25
 72 31%

Report created on February 11, 2012.